These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 11328668)
1. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells. Kang YS; Voigt K; Bickel U J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668 [TBL] [Abstract][Full Text] [Related]
2. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). Jeong Lee H; Pardridge WM J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Kang YS; Bickel U; Pardridge WM Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery. Bickel U; Yamada S; Pardridge WM J Pharmacol Exp Ther; 1994 Feb; 268(2):791-6. PubMed ID: 8113991 [TBL] [Abstract][Full Text] [Related]
5. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. Yoshikawa T; Pardridge WM J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. Wu D; Boado RJ; Pardridge WM J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431 [TBL] [Abstract][Full Text] [Related]
7. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. Kang YS; Pardridge WM J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841 [TBL] [Abstract][Full Text] [Related]
8. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. Wu D; Pardridge WM J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978 [TBL] [Abstract][Full Text] [Related]
9. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898 [TBL] [Abstract][Full Text] [Related]
10. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Deguchi Y; Kurihara A; Pardridge WM Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961 [TBL] [Abstract][Full Text] [Related]
11. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622 [TBL] [Abstract][Full Text] [Related]
12. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate. Li XB; Liao GS; Shu YY; Tang SX J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183 [TBL] [Abstract][Full Text] [Related]
13. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. Cerletti A; Drewe J; Fricker G; Eberle AN; Huwyler J J Drug Target; 2000; 8(6):435-46. PubMed ID: 11328669 [TBL] [Abstract][Full Text] [Related]
14. Brain iron homeostasis. Moos T Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165 [TBL] [Abstract][Full Text] [Related]
15. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. Bickel U; Kang YS; Pardridge WM Bioconjug Chem; 1995; 6(2):211-8. PubMed ID: 7599264 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Kang YS; Boado RJ; Pardridge WM Drug Metab Dispos; 1995 Jan; 23(1):55-9. PubMed ID: 7720525 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Wu D; Pardridge WM Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674 [TBL] [Abstract][Full Text] [Related]
18. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Saito Y; Buciak J; Yang J; Pardridge WM Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. Wu D; Song BW; Vinters HV; Pardridge WM J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825 [TBL] [Abstract][Full Text] [Related]
20. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pardridge WM; Wu D; Sakane T Pharm Res; 1998 Apr; 15(4):576-82. PubMed ID: 9587954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]